• Indication
    • Uveitis (macular edema associated with uveitis)

      Diabetic Macular Edema

    • Progressive Myopia

    • Presbyopia

    • Corneal endothelial dysfunction

    • Dry Eye

    • Glaucoma

  • Commercial Rights
    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China & South Korea

    • Greater China, South Korea, ASEAN countries

    • Global

  • Partners
    • Preclinical
    • Phase I
    • Phase II
    • Phase III / Pivotal Study
    • NDA / Regulatory Approval
    • Marketed
    • US
    • US
    • US
    • JP
    • US
    • *
    Arctic Vision China R&D Progress Partners R&D Progress

Arctic Vision is a clinical stage ophthalmology company focused on developing breakthrough therapies with high commercial value to address the unmet clinical needs. Our vision is to become a leading ophthalmology company in China and lead China's ophthalmology market. Arctic Vision is established by top-tier life sciences investors, and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. 

  • Eddy WuPh.D.
    Founder and CEO
  • Qing Liu M.D., Ph.D.
    Chief Medical Officer
  • York Chen M.D., EMBA
    Chief Commercial Officer
  • Simon TsangPh.D.
    Chief Business Officer
  • Ping ChengCA/CFA
    Associate Vice President, Finance
  • Jindong DingPh.D.
    Associate Vice President, Science and Research
  • Katherine HeNY Bar
    Sr. Legal Director, Legal
Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China
Copyright © 2020 Arctic Vision (Shanghai) Biotechnology Co., Ltd.